Skip to Content
MilliporeSigma
All Photos(1)

Documents

B1054000

Betamethasone 17-valerate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1,4-Pregnadiene-11β,17α,21-triol-9α-fluoro-16β-methyl-3,20-dione 17-valerate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17-valerate, 9α-Fluoro-16β-methylprednisolone 17-valerate, Betnovate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H37FO6
CAS Number:
2152-44-5
Molecular Weight:
476.58
Beilstein/REAXYS Number:
4240001
MDL number:
MFCD00867446
UNSPSC Code:
41116107
PubChem Substance ID:
329773158
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

betamethasone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO

InChI

1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19?,20?,21-,24-,25-,26-,27-/m0/s1

InChI key

SNHRLVCMMWUAJD-QDHNOTTGSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Betamethasone 17-valerate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1067001

Betamethasone acetate, United States Pharmacopeia (USP) Reference Standard

1067704

Betamethasone dipropionate, United States Pharmacopeia (USP) Reference Standard

1069007

Betamethasone valerate, United States Pharmacopeia (USP) Reference Standard

1068004

Betamethasone sodium phosphate, United States Pharmacopeia (USP) Reference Standard

B1055000

Betamethasone 21-valerate, European Pharmacopoeia (EP) Reference Standard

B1000000

Betamethasone, European Pharmacopoeia (EP) Reference Standard

B1030000

Betamethasone acetate, European Pharmacopoeia (EP) Reference Standard

B1040000

Betamethasone dipropionate, European Pharmacopoeia (EP) Reference Standard

B1045000

Betamethasone sodium phosphate, European Pharmacopoeia (EP) Reference Standard

Y0001065

Betamethasone valerate impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0001027

Betamethasone valerate for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1398

Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1399

Betamethasone Dipropionate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001416

Betamethasone dipropionate for peak identification, European Pharmacopoeia (EP) Reference Standard

1066009

Betamethasone, United States Pharmacopeia (USP) Reference Standard

1069018

Betamethasone Valerate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1067307

Betamethasone benzoate, United States Pharmacopeia (USP) Reference Standard

PHR1779

Betamethasone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001925

Betamethasone dipropionate for system suitability A, European Pharmacopoeia (EP) Reference Standard

BP041

Betamethasone sodium phosphate, British Pharmacopoeia (BP) Reference Standard

BP575

Betamethasone, British Pharmacopoeia (BP) Reference Standard

BP043

Betamethasone 21-valerate, British Pharmacopoeia (BP) Reference Standard

BP042

Betamethasone valerate, British Pharmacopoeia (BP) Reference Standard

1067045

Betamethasone Acetate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1067726

Betamethasone Dipropionate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1067737

Betamethasone Dipropionate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1067760

Betamethasone Dipropionate Related Compound F , United States Pharmacopeia (USP) Reference Standard

1067781

Betamethasone dipropionate Related Compound H, United States Pharmacopeia (USP) Reference Standard

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 2

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Luigi Naldi et al.
American journal of clinical dermatology, 12(3), 191-201 (2011-02-03)
Corticosteroids are a versatile option for the treatment of mild-to-moderate psoriasis due to their availability in a wide range of potencies and formulations. Occlusion of the corticosteroid is a widely accepted procedure to enhance the penetration of the medication, thereby
Jin Zhang et al.
Journal of pharmaceutical sciences, 100(3), 896-903 (2010-09-15)
Corticosteroids are therapeutic agents widely used in the pharmacological treatment of skin diseases such as eczema or psoriasis. Unfortunately, their use is restricted by the side effects that frequently occur at the systemic level. The goal of the research described
Jayalakshmi Somuramasami et al.
Journal of pharmaceutical and biomedical analysis, 54(1), 242-247 (2010-09-11)
Currently, there are no analytical methods available in the literature that can simultaneously separate and quantitate residual levels of acetone, methylene chloride, n-butyl ether and dimethylsulfoxide in Betamethasone valerate active pharmaceutical ingredient (API). This paper describes the development and validation
Rosita Saraceno et al.
The Journal of dermatological treatment, 21(6), 363-366 (2010-06-12)
Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus. To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis. Twelve patients were
Paiboon Sookpotarom et al.
Pediatric surgery international, 29(4), 393-396 (2013-01-08)
0.05 % betamethasone valerate cream is generally used as an alternative to circumcision for the treatment of phimosis in boys. The aim of this study is to determine whether the half-strength formula (0.025 %) of betamethasone is as effective as 0.05 % betamethasone.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service